Menu Back to DIA-Global-Oncology-Development-2020


Online Registration has been closed. Onsite Registration will be available at Nihonbashi Life Science HUB.

This program will be conducted in Japanese Language only.

Click Here to View the program in Japanese


The world surrounding cancer treatment continues to evolve rapidly. New, emerging products include not only immuno-oncology drugs, but also regenerative medicine and medical devices, that expand the therapeutic choice in the field of cancer treatment. There are plenty of new topics, such as the remarkable progress of genome analysis technology toward truly personalized medicine, new regulatory frameworks of accelerated approval and Sakigake designation, proposals of innovative clinical trial designs that enable evidence building for rare cancers, better utilization of real world data, and many more. Thanks to the rapidly evlolving digital applications, artificial intelligence (AI), and the Internet of Things (IoT) that affect clinical trial operations, clinical development faces both challenge and opportunity to keep the evaluation of  novel therapeutic products simple and reliable. In addition, as clinical trials are increasingly recognized as a part of “Patients’s Journey”, the demand for improvement of access to the cancer clinical trials has become stronger.


What are we supposed to do in the face of such tide of rapid change in this field? What can we do for the patients in the world who are facing and battling cancer daily? There are growing number of people who disclose that they are cancer patients and influence the public’s image, knowledge and expectations of cancer and its treatment by sharing their story of daily struggles and experiences. Clearly, there is a need for a new stage of discussion on various aspects of potential progress in cancer treatment from a new perspective, free from biased views based on our past successes.


This conference provides a great opportunity to share the latest information about changes in the clinical trial environment (including new trial designs), integration of information technology (IT) into medical care, new development strategies, and to explore the future of cancer treatment. Thank you for your participation.

Program Committee

  • Toshihiko  Doi, MD, PhD
    Toshihiko Doi, MD, PhD Deputy Director / Chief, Experimental Therapeutics
    National Cancer Center Hospital East, Japan
  • Noboru  Yamamoto, MD, PhD
    Noboru Yamamoto, MD, PhD Deputy Director, Department of Experimental Therapeutics
    National Cancer Center Hospital, Japan
  • Masakazu  Hirata, MD, PhD
    Masakazu Hirata, MD, PhD Review Director, Office of New Drug V
    Pharmaceuticals and Medical Devices Agency (PMDA), Japan
  • Toshiko  Ishibashi, PhD, RN
    Toshiko Ishibashi, PhD, RN Clinical Operation I, Clinical Operation Management
    Ono Pharmaceutical Co., Ltd., Japan
  • Eri  Sekine
    Eri Sekine Department Head, Trial Monitoring, Japan Development, Global Development Ops.
    Novartis Pharma K.K., Japan
  • Takuya  Suzuki
    Takuya Suzuki Associate Director, Japan anad Asia Clinical Development Department
    Eisai Co., Ltd., Japan
    TOMOKO TAKAMI Director, Oncology Clinical Development, Oncology Science Unit
    MSD K.K., Japan
  • Atsushi  Tsukamoto, PhD, MSc
    Atsushi Tsukamoto, PhD, MSc
    Daiichi Sankyo Company, Limited, Japan
  • Hironobu  Saito, PhD
    Hironobu Saito, PhD Corporate Officer /Head of Medical Affairs Div.
    Daiichi Sankyo Co., Ltd., Japan
  • Junko  Sato, PhD
    Junko Sato, PhD Director, Office of International Programs
    Pharmaceuticals and Medical Devices Agency (PMDA), Japan
Load More

Contact us

Please contact DIA Japan for further information.

Send Email

Digital Learning Catalog

DIA Learning: eLearning Soultions